In summary, we have illustrated EPO could be directly secreted from the tumors of a subgroup of NSCLC patients, and the tumor derived EPO was capable of promoting the dual EPO and EPOR-positive NSCLC progression. This evidence concerns the gene EPOR and non-small cell lung carcinoma.